24.62
3.49%
+0.83
시간 외 거래:
24.75
0.13
+0.53%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Nikko Asset Management Americas Inc. - MarketBeat
MarketBeat
Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Increases By 6.5% - MarketBeat
MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $40.18 Average Target Price from Analysts - MarketBeat
MarketBeat
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European ... - Yahoo Finance
Yahoo Finance
68,050 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by International Assets Investment Management ... - MarketBeat
MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Up 10.1% - MarketBeat
MarketBeat
Cantor Fitzgerald Weighs in on Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM) - MarketBeat
MarketBeat
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn - Simply Wall St
Simply Wall St
Cantor Fitzgerald Weighs in on Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM) - Defense World
Defense World
Analysts Issue Forecasts for Beam Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:BEAM) - Defense World
Defense World
Wedbush Brokers Boost Earnings Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
MarketBeat
Q3 2024 EPS Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) Lifted by Leerink Partnrs - Defense World
Defense World
Beam Therapeutics (NASDAQ:BEAM) Given New $33.00 Price Target at Barclays - Defense World
Defense World
Research Analysts Set Expectations for Beam Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:BEAM) - Defense World
Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by First Horizon Advisors Inc. - Defense World
Defense World
(BEAM) Investment Analysis and Advice - Stock Traders Daily
Stock Traders Daily
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind ... - Yahoo Finance
Yahoo Finance
Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind ... - Yahoo Finance
Yahoo Finance
Bridge beams put in as residents invited to watch - Yahoo New Zealand News
Yahoo New Zealand News
Beam Therapeutics (NASDAQ:BEAM) Announces Earnings Results - MarketBeat
MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Price Target Lowered to $33.00 at Barclays - MarketBeat
MarketBeat
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss - Yahoo Finance Australia
Yahoo Finance Australia
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss - Zacks Investment Research
Zacks Investment Research
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference - GlobeNewswire
GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference - EIN News
EIN News
Beam Therapeutics (NASDAQ:BEAM) Stock Rating Reaffirmed by Wedbush - Defense World
Defense World
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine - InvestorPlace
InvestorPlace
Beam Therapeutics (NASDAQ:BEAM) Rating Reiterated by Wedbush - MarketBeat
MarketBeat
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview - GuruFocus.com
GuruFocus.com
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results - Yahoo Finance
Yahoo Finance
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies - Yahoo Movies Canada
Yahoo Movies Canada
Vestmark Advisory Solutions Inc. Makes New $2.67 Million Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
MarketBeat
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Top 5 CRISPR Companies To Invest In (May 2024) - Securities.io
Securities.io
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
Expert Ratings For Beam Therapeutics
Benzinga
Expert Ratings For Beam Therapeutics - Beam Therapeutics (NASDAQ:BEAM) - Benzinga
Benzinga
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing - TipRanks.com - TipRanks
TipRanks
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Yahoo Finance
How To Trade (BEAM) - Stock Traders Daily
Stock Traders Daily
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S - Simply Wall St
Simply Wall St
Beam Therapeutics CEO sells shares worth over $2 million - Investing.com
Investing.com
(BEAM) Long Term Investment Analysis - Stock Traders Daily
Stock Traders Daily
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - TipRanks.com - TipRanks
TipRanks
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - Markets Insider
Markets Insider
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Zacks Investment Research
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? - Yahoo Finance
Yahoo Finance
자본화:
|
볼륨(24시간):